PAR DRUGS AND CHEM LTD

Q1 FY27, unaudited

Revenue: ₹31.28 Cr
Profit after tax: ₹4.71 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ crore	Q1 FY27	vs a year ago	FY26
Revenue from operations	31.28	+20.10%	103.66
Other income	0.94	−49.08%	4.00
Total income	32.22	+15.54%	107.66
Employee benefit expense	1.69	+18.98%	6.12
Finance costs	0.02	+31.29%	0.13
Depreciation & amortisation	0.96	+6.72%	3.70
Total expenses	25.89	+10.60%	90.35
Profit before tax	6.33	+41.37%	17.30
Tax expense	1.62	+40.68%	4.19
Profit after tax	4.71	+41.60%	13.11
Total comprehensive income	4.71	+41.60%	13.11

Earnings per share
Earnings per share, basic	₹3.83	₹10.65
Earnings per share, diluted	₹3.83	₹10.65

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

PAR DRUGS AND CHEM LTD has not filed a concall transcript in the last 4 quarters.

Filings

0 shown · 0 published by the exchange

The exchange has published no filings for this company in the period Parakho holds.

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.